Table 1 Baseline Characteristics
Variable | CPT [n = 52; n (%)] | Standard Care [n = 55; n (%)] | P-value |
|---|---|---|---|
Sex | 0.482a | ||
Male | 22 (42.31) | 27 (49.09) | |
Female | 30 (57.69) | 28 (50.91) | |
Age in years, median (IQR) | 61 (45–66.5) | 71 (61–77) | < 0.001b |
BMI in kg/m2, median (IQR) | 26.67 (23.53–31.63) | 25.63 (22.04–29.52) | 0.257c |
< 31 | 24 (60.00) | 38 (80.85) | 0.106d |
31–35 | 10 (25.00) | 6 (12.77) | |
> 35 | 6 (15.00) | 3 (6.38) | |
Comorbidity | 43 (82.69) | 36 (69.23) | 0.108a |
Hypertension | 29 (55.77) | 32 (61.54) | 0.550a |
Diabetes Mellitus | 25 (48.08) | 21 (40.38) | 0.430a |
Cerebrovascular disease | 1 (1.92) | 1 (1.92) | 1.000d |
Chronic kidney disease | 5 (9.62) | 10 (19.23) | 0.163a |
End stage renal disease | 1 (1.92) | 1 (1.92) | 1.000d |
Cancer | 1 (1.92) | 1 (1.92) | 1.000d |
Ischemic Heart Disease | 1 (1.92) | 6 (11.54) | 0.112d |
Others | 3 (5.76) | 2 (3.64) | 0.679b |
Duration from the onset of symptoms to the admission day (days), median (IQR) | 5.5 (0–19) | 4 (0–16) | 0.067b |
Receiving dexamethasone | 52/52 (100%) | 55/55 (100%) | 1.000 |
Receiving RdRp inhibitor treatment | 52/52 (100%) | 55/55 (100%) | 1.000 |
Day of dexamethasone treatment, median (IQR) | 8 (0–14) | 6 (1–20) | 0.507c |
Day of RdRp inhibitors treatment, median (IQR) | 10 (5–10) | 5.5 (1–10) | 0.016c |
Day of CPT after the onset of symptoms, median (IQR) | 9 (6–13) | 0 | – |
Day of CPT after admission, median (IQR) | 2 (1–3) | 0 | – |
The lowest SpO2 from admission to deterioration, median (IQR) | 91 (68–95) | 87 (15–95) | 0.007b |
Duration from the day of admission to critical illness (days), median (IQR) | 5 (0–19) | 0 (0–13) | < 0.001b |